Acrivon Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
ACRV$1.57-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-InCapital | AccumulatedOtherComprehensiveIncome (Loss) | AccumulatedDeficit | TotalStockholders’Equity | |
| Balance at December 31, 2025 | 31,648,856 | $31 | $387,255 | $111 | $(274,881) | $112,516 |
| Issuance of common stock upon exercise of pre-funded warrants | 7,056,101 | 7 | (7) | — | — | — |
| Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax | 40,075 | — | (33) | — | — | (33) |
| Stock-based compensation expense | — | — | 2,181 | — | — | 2,181 |
| Unrealized loss on available-for-sale investments, net of tax | — | — | — | (107) | — | (107) |
| Net loss | — | — | — | — | (19,042) | (19,042) |
| Balance at March 31, 2026 | 38,745,032 | $38 | $389,396 | $4 | $(293,923) | $95,515 |
| Issuance of common stock under at-the-market offering, net of issuance costs of $336 | 4,054,954 | 4 | 6,959 | — | — | 6,963 |
| Exercise of common stock options | 8,110 | — | 8 | — | — | 8 |
| Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax | 39,119 | — | (34) | — | — | (34) |
| Stock-based compensation expense | — | — | 2,214 | — | — | 2,214 |
| Unrealized loss on available-for-sale investments, net of tax | — | — | — | (37) | — | (37) |
| Net loss | — | — | — | — | (17,964) | (17,964) |
| Balance at June 30, 2026 | 42,847,215 | $42 | $398,543 | $(33) | $(311,887) | $86,665 |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-InCapital | AccumulatedOtherComprehensiveIncome (Loss) | AccumulatedDeficit | TotalStockholders’Equity | |
| Balance at December 31, 2024 | 31,231,264 | $31 | $373,284 | $447 | $(196,976) | $176,786 |
| Exercise of common stock options | 225 | — | 1 | — | — | 1 |
| Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax | 120,578 | — | (344) | — | — | (344) |
| Stock-based compensation expense | — | — | 3,791 | — | — | 3,791 |
| Unrealized loss on available-for-sale investments, net of tax | — | — | — | (164) | — | (164) |
| Net loss | — | — | — | — | (19,680) | (19,680) |
| Balance at March 31, 2025 | 31,352,067 | $31 | $376,732 | $283 | $(216,656) | $160,390 |
| Issuance of common stock upon vesting of restricted stock units, net of shares withheld for tax | 97,677 | — | (97) | — | — | (97) |
| Stock-based compensation expense | — | — | 3,927 | — | — | 3,927 |
| Unrealized loss on available-for-sale investments, net of tax | — | — | — | (177) | — | (177) |
| Net loss | — | — | — | — | (21,006) | (21,006) |
| Balance at June 30, 2025 | 31,449,744 | $31 | $380,562 | $106 | $(237,662) | $143,037 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.